Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01185964 · ClinicalTrials.gov registry record · Phase 1
A Study of Olaratumab in Soft Tissue Sarcoma
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT01185964: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01185964 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 148 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01185964, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.
Primary Outcome
PFS is measured from randomization until the first radiographic documentation of progression of disease (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) or death from any cause. Participants who died without PD was considered to have progressed on the day of death. The following censoring rules applied: If no radiologic assessment at baseline or post baseline, participant was censored at the date of randomization. Participants were censored at the day of the
Interventions
- DRUG doxorubicin
- BIOLOGICAL Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2010-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT01185964 record still lists
NCT01185964 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 2 interventions - of which doxorubicin is the first listed.
NCT01185964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01185964 about?
NCT01185964 is a clinical study titled "A Study of Olaratumab in Soft Tissue Sarcoma". The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.
What is the current status of trial NCT01185964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2010-10. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01185964?
The interventions under investigation include: doxorubicin (DRUG), Olaratumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01185964?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01185964's enrollment target sits among peer trials
148 382nd of 2000 higher than 1,614 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia